HomeCompareXLNX vs ABBV

XLNX vs ABBV: Dividend Comparison 2026

XLNX yields 8.04% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $73.7K in total portfolio value
10 years
XLNX
XLNX
● Live price
8.04%
Share price
$194.92
Annual div
$15.68
5Y div CAGR
-8.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.6K
Annual income
$493.88
Full XLNX calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — XLNX vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXLNXABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XLNX + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XLNX pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XLNX
Annual income on $10K today (after 15% tax)
$683.77/yr
After 10yr DRIP, annual income (after tax)
$419.80/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $20,636.21/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XLNX + ABBV for your $10,000?

XLNX: 50%ABBV: 50%
100% ABBV50/50100% XLNX
Portfolio after 10yr
$65.5K
Annual income
$12,632.82/yr
Blended yield
19.30%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

XLNX
Analyst Ratings
16
Buy
28
Hold
1
Sell
Consensus: Hold
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XLNX buys
0
ABBV buys
0
No recent congressional trades found for XLNX or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXLNXABBV
Forward yield8.04%3.06%
Annual dividend / share$15.68$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-8.1%40.6%
Portfolio after 10y$28.6K$102.3K
Annual income after 10y$493.88$24,771.77
Total dividends collected$6.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: XLNX vs ABBV ($10,000, DRIP)

YearXLNX PortfolioXLNX Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,439$739.27$11,550$430.00$111.00ABBV
2$12,966$726.33$13,472$627.96$506.00ABBV
3$14,581$707.11$15,906$926.08$1.3KABBV
4$16,285$682.95$19,071$1,382.55$2.8KABBV
5$18,080$655.11$23,302$2,095.81$5.2KABBV
6$19,970$624.68$29,150$3,237.93$9.2KABBV
7$21,961$592.62$37,536$5,121.41$15.6KABBV
8$24,058$559.72$50,079$8,338.38$26.0KABBV
9$26,268$526.64$69,753$14,065.80$43.5KABBV
10$28,601$493.88$102,337$24,771.77$73.7KABBV

XLNX vs ABBV: Complete Analysis 2026

XLNXStock

Xilinx, Inc. designs, develops, and markets programmable devices and associated technologies worldwide. The company offers integrated circuits (ICs) in the form of programmable logic devices (PLDs), such as programmable system on chips, and three dimensional ICs; adaptive compute acceleration platform; software design tools to program the PLDs; software development environments and embedded platforms; targeted reference designs; printed circuit boards; and intellectual property (IP) core licenses covering Ethernet, memory controllers, Interlaken, and peripheral component interconnect express interfaces, as well as domain-specific IP in the areas of embedded, digital signal processing and connectivity, and market-specific IP cores. It also offers development boards; development kits, including hardware, design tools, IP, and reference designs that are designed to streamline and accelerate the development of domain-specific and market-specific applications; and configuration products comprising one-time programmable and in-system programmable storage devices to configure field programmable gate arrays. In addition, it provides design, customer training, field engineering, and technical support services. The company offers its products to electronic equipment manufacturers in sub- markets, such as data center, wireless, wired, aerospace and defense, test, measurement and emulation, industrial, scientific and medical, automotive, audio, video and broadcast, and consumer. It sells its products through a network of independent distributors; and through direct sales to original equipment manufacturers and electronic manufacturing service providers, as well as independent sales representatives. Xilinx, Inc. was incorporated in 1984 and is headquartered in San Jose, California. As of February 14, 2022, Xilinx, Inc. operates as a subsidiary of Advanced Micro Devices, Inc.

Full XLNX Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this XLNX vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XLNX vs SCHDXLNX vs JEPIXLNX vs OXLNX vs KOXLNX vs MAINXLNX vs JNJXLNX vs MRKXLNX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.